Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries
A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries
Sponsor: C. R. Bard
Listed as NCT02278991, this observational or N/A phase trial focuses on Peripheral Artery Disease and remains completed. Sponsored by C. R. Bard, it has been updated 12 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Nov 2019 — Jan 2021 [monthly]
Completed
▶ Show 7 earlier versions
-
Sep 2019 — Nov 2019 [monthly]
Completed
-
Dec 2018 — Sep 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
-
May 2017 — Jan 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- C. R. Bard
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arnsberg, Germany, Bad Bevensen, Germany, Bad Krozingen, Germany, Hamburg, Germany, Immenstadt im Allgäu, Germany, Kassel, Germany, Lübeck, Germany, Pátrai, Greece, Rosenheim, Germany, Sanok, Poland and 2 more location s